---
schema_version: "secwatch.filing_event.v1"
accession: "0001828185-26-000018"
form_type: "8-K"
ticker: "BRNS"
cik: "0001828185"
company_name: "Barinthus Biotherapeutics plc."
filed_at: "2026-04-30T23:59:59+00:00"
generated_at: "2026-05-15T01:05:13.125278+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Barinthus Bio Q1 net loss narrows to $5.5M; merger with Clywedog on track

## Summary
- Net loss of $5.5M ($0.14/shr) vs $19.6M ($0.49/shr) in Q1 2025.
- Cash $67.2M at March 31, 2026; post-merger cash runway expected through 2027.
- Merger with Clywedog expected mid-2026; combined company to trade as CLYD.
- Doug Swirsky appointed CFO effective May 1, 2026.
- VTP-1000 celiac trial data from multiple ascending dose portion expected H2 2026.

## SEC filing metadata
- accession: 0001828185-26-000018
- form_type: 8-K
- ticker: BRNS
- cik: 0001828185
- company_name: Barinthus Biotherapeutics plc.
- filed_at: 2026-04-30T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000018/0001828185-26-000018-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000018/brns-20260430.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001828185-26-000018
- JSON: https://secwatch.observer/filing/0001828185-26-000018.json
- Plain text: https://secwatch.observer/filing/0001828185-26-000018.txt

## Key facts
- Earnings Releases
  Barinthus Biotherapeutics plc. reported quarter ended March 31, 2026 results: net income net loss attributable to its shareholders of $5.5 million, or $(0.14) per share, EPS $(0.14) per share.
  - Period: quarter ended March 31, 2026
  - Net income: net loss attributable to its shareholders of $5.5 million, or $(0.14) per share
  - EPS: $(0.14) per share
  - Result: reported results
  source text: For the first quarter of 2026, the Company generated a net loss attributable to its shareholders of $5.5 million, or $(0.14) per share on both basic and fully diluted bases
  evidence_url: https://www.sec.gov/Archives/edgar/data/1828185/000182818526000018/0001828185-26-000018-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.